Effect of magnesium sulfate on blood coagulation status in pregnant women with preeclampsia

According to some studies, magnesium in pharmacological concentrations has antithrombotic effects, causing platelet dysfunction in vitro and in vivo. This study was performed with aim to evaluate the effect of magnesium sulfate on blood coagulation status in pregnant women with preeclampsia.

This cross-sectional study was performed in 2013-2014 on 56 pregnant women with mild preeclampsia. Platelet count and magnesium levels, bleeding time (BT), prothrombin time (PT), and activated partial thromboplastin time (aPTT) were measured before and two hours after magnesium sulfate injection. Data were collected and analyze by SPSS software (version 16) and paired t-test and Chi-square test. P<0.05 was considered statistically significant.

Mean serum magnesium level in the patients was 4.53 ± 0.51 mEq/L. Mean platelet count of patients before and after prescribing magnesium were 176.55±43.84 ×1000 vs 173.25±51.51×1000, respectively; no significant difference was observed (P=0.108). Mean PT (prothrombin time) before and after the treatment was 13.36 ± 0.69 seconds vs 13.57± 0.79 seconds, respectively. There was no significant difference between PT before and after treatment (P = 0.059). Mean PTT (partial thromboplastin time) before and after the treatment was 38.1± 2.05 and 38.26± 2.92 seconds, respectively. There was no significant difference between PTT before and after treatment (P=0.756). Mean BT of women before and after magnesium administration were 109.55±39.7 vs 123.48±44.87, respectively (P=0.013).

BT in therapeutic values increased in pregnant women after prescribing magnesium sulfate.